Human Molecular Genetics Advance Access originally published online on January 9, 2007
Human Molecular Genetics 2007 16(5):515-528; doi:10.1093/hmg/ddl484
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reduced perlecan in mice results in chondrodysplasia resembling Schwartz–Jampel syndrome
1 Department of Animal Biology, University of Pennsylvania School of Veterinary Medicine, 3800 Spruce Street, Rosenthal Room 152, Pennsylvania, PA 19104-6046, USA and 2 Department of Molecular Medicine, Max Planck Institute of Biochemistry, Am Klopferspitz 18a, 82152 Martinsried, Germany
* To whom correspondence should be addressed. Tel: +1 2155739448; Fax: +1 2155735188; Email: krodgers{at}vet.upenn.edu
Received November 21, 2006; Accepted December 28, 2006
Perlecan knock-in mice were developed to model Schwartz–Jampel syndrome (SJS), a skeletal disease resulting from decreased perlecan. Two mouse strains were generated: those carrying a C-to-Y mutation at residue 1532 and the neomycin cassette (C1532Yneo) and those harboring the mutation alone (C1532Y). Immunostaining, biochemistry, size measurements, skeletal studies and histology revealed Hspg2 transcriptional changes in C1532Yneo mice, leading to reduced perlecan secretion and a skeletal disease phenotype characteristic of SJS patients. Skeletal disease features include smaller size, impaired mineralization, misshapen bones, flat face and joint dysplasias reminiscent of osteoarthritis and osteonecrosis. Moreover, C1532Yneo mice displayed transient expansion of hypertrophic cartilage in the growth plate concomitant with radial trabecular bone orientation. In contrast, C1532Y mice, harboring only the mutation associated with SJS, displayed a mild phenotype, inconsistent with SJS. These studies question the C1532Y mutation as the sole causative factor of SJS in the human family harboring this alteration and imply that transcriptional changes leading to perlecan reduction may represent the disease mechanism for SJS.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Serrat, R. M. Williams, and C. E. Farnum Temperature alters solute transport in growth plate cartilage measured by in vivo multiphoton microscopy J Appl Physiol, June 1, 2009; 106(6): 2016 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stum, E. Girard, M. Bangratz, V. Bernard, M. Herbin, A. Vignaud, A. Ferry, C.-S. Davoine, A. Echaniz-Laguna, F. Rene, et al. Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz-Jampel syndrome neuromyotonia Hum. Mol. Genet., October 15, 2008; 17(20): 3166 - 3179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Zoeller, A. McQuillan, J. Whitelock, S.-Y. Ho, and R. V. Iozzo A central function for perlecan in skeletal muscle and cardiovascular development J. Cell Biol., April 21, 2008; 181(2): 381 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C Farach-Carson and D. D Carson Perlecan a multifunctional extracellular proteoglycan scaffold Glycobiology, September 1, 2007; 17(9): 897 - 905. [Abstract] [Full Text] [PDF]
|
|